Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF
Jascayd is said to be the first phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic and immunomodulatory effects to be approved for these uses. Japan is the fourth country to
Jascayd is said to be the first phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic and immunomodulatory effects to be approved for these uses. Japan is the fourth country to
Data from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials support these approvals. They cover the use of Enhertu in both the neoadjuvant and adjuvant treatment settings for adult
The companies are also launching their first collaboratively developed product, Aridol, and plan to introduce further branded products in the future. The collaboration integrates Arna Pharma’s development expertise
Affecting adults and children, this rare, progressive, genetic disorder impacts both bone and muscle health due to the body’s inability to retain sufficient phosphorus, a mineral essential for
The offer was approved by Assertio’s Board of Directors, following a revised merger agreement process and is considered a “superior proposal” compared to the previous agreement with Garda
The approval covers adults and adolescents in the European Union (EU) who weigh at least 35kg and have haemophilia A (factor VIII deficiency) with factor VIII inhibitors, or
With this authorisation, the UAE is said to become the first nation worldwide to approve this treatment, which is offered in 1mg and 2mg doses. This move underscores
The round was led by Thrive Capital, with participation from existing investors Alphabet and GV, as well as new investors CapitalG, MGX, Temasek, and the UK Sovereign AI
The move leverages CTTQ’s extensive reach and portfolio in liver disease, covering more than 5,000 medical centres in China. Under this agreement, the company will manage the importation,
The approval process was accelerated after Partner Therapeutics received the FDA Commissioner’s National Priority Voucher. Bizengri has already received breakthrough therapy and orphan drug designations for this indication.